eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank



1/2021
vol. 8
 
Share:
Share:
more
 
 
abstract:
Review paper

Immunotherapy – the causes of sub-optimal efficacy in inhaled allergies

Marita Nittner-Marszalska
1

1.
Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Uniwersytet Medyczny we Wrocławiu
Alergologia Polska – Polish Journal of Allergology 2021; 8, 1: 31–39
Online publish date: 2021/03/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Allergen immunotherapy (AIT) has proven efficacy in IgE-dependent respiratory diseases. When AIT is conducted continnuosly for 3 years, it confers long-term clinical benefits after cessation of treatment. While multiple studies confirm high efficacy of AIT, there are some patients who do not respond to this therapy (“non-responders”) or find its results non-satisfactory (“poor-responders”). What factors may be responsible for lack of a therapeutic success of AIT or the therapy’s not fully optimal result? How to predict AIT treatment failures? Can biomarkers facilitate the prediction? How to identify patients who may turn out to be treatment failures? The article sets forth causes of AIT failures: wrong diagnosis of the underlying allergic disease, selection of a clinically non-important allergen for AIT, lack of sensibilization to the major allergen and badly performed AIT. In regard to AIT success of failure, additionally addressed is the issue of heterogeneity of molecular profiles and the sensibilization to clinically important molecules like Der p 23.
keywords:

allergen immunotherapy, biomarkers, efficacy, sensibilisation heterogeneity, component resolved diagnosis, Der p 23

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe